A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies by Lachowiez, CA, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, GD, Smith, S, Garcia, JS, Bose, P, Jabbour, E, Ravandi, F, Daver, NG, Garcia-Manero, G, Stoilova, B, Vyas, P, Kantarjian, HM, Konopleva, M, Dinardo, CD

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies by Lachowiez, CA, Garcia, JS, Borthakur, G, Loghavi, S, Zeng, Z, Tippett, GD, Kadia, TM, Masarova, L, Yilmaz, M, Maiti, A, Bose, P, Takahashi, K, Jabbour, E, Ravandi, F, Daver, NG, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, Dinardo, CD

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies by Lachowiez, CA, Loghavi, S, Zeng, Z, Tanaka, T, Kim, YJ, Uryu, H, Turkalj, S, Jakobsen, NA, Luskin, MR, Duose, DY, Tidwell, RSS, Short, NJ, Borthakur, G, Kadia, TM, Masarova, L, Tippett, GD, Bose, P, Jabbour, EJ, Ravandi, F, Daver, NG, Garcia-Manero, G, Kantarjian, H, Garcia, JS, Vyas, P, Takahashi, K, Konopleva, M, DiNardo, CD